Apretude Shortage Update: What Patients Need to Know in 2026

If you've been searching for information about an Apretude shortage, here's the quick answer: as of 2026, Apretude is not listed on the FDA Drug Shortage Database, and manufacturer ViiV Healthcare has not reported any supply disruptions. But many patients are still having trouble accessing it — and that frustration is completely valid.

The real story is more nuanced than a simple "shortage" or "no shortage" answer. Here's everything patients need to know.

Is Apretude in a Shortage Right Now?

No. As of early 2026, the FDA has not placed Apretude on the Drug Shortage Database. ViiV Healthcare continues to manufacture cabotegravir extended-release injectable suspension and distribute it through specialty pharmacy channels. There are no published reports of manufacturing disruptions, supply constraints, or import alerts affecting Apretude.

So Why Is Apretude Hard to Access?

Apretude's access challenges are structural, not supply-based. Unlike oral PrEP medications you pick up at a pharmacy, Apretude is a specialty injectable that must be administered by a healthcare provider in a clinical setting. This means:

It's not stocked at retail pharmacies — it flows through specialty pharmacy channels to clinical providers

Not all clinics are yet set up to administer injectable PrEP (training, billing infrastructure, specialty pharmacy partnerships)

Insurance prior authorization can take 2-4 weeks even when coverage is theoretically mandated

Rural and underserved areas have fewer providers offering injectable PrEP overall

A Brief History of Apretude Access Since FDA Approval

Apretude was FDA approved in December 2021 — the first long-acting injectable PrEP option ever approved. In the years since, ViiV Healthcare and healthcare systems have been working to build the infrastructure needed to widely deliver it:

2021: FDA approval; early adopter clinics begin offering it at HIV specialty centers

2022-2023: Broader rollout; community health centers begin building infrastructure; ACA coverage mandate takes effect

2024: Medicare coverage at $0 for eligible beneficiaries confirmed; insurance billing workflows improve across more practices

2025: More than 3 years of real-world data; over 5,000 patient-years of clinical trial data; provider adoption continues to grow

2026: Access continues improving but geographic disparities remain, particularly in rural areas

What the ACA Coverage Mandate Means for You

The Affordable Care Act (ACA) requires most private insurance plans to cover Grade A USPSTF preventive services with no cost-sharing. The USPSTF has given PrEP a Grade A recommendation, which means Apretude — along with related HIV testing and clinical visits — should be covered at $0 cost-share under most ACA-compliant private plans.

Medicare also covers Apretude and related preventive services at $0 for beneficiaries at increased HIV risk. However, billing practices vary and some patients have been incorrectly charged cost-sharing despite the mandate. If this happens to you, contact your insurer to dispute the charges.

What Should I Do If I Can't Find Apretude?

Here are your best options:

Use medfinder to locate providers near you who can administer Apretude. Visit medfinder.com and enter your medication and zip code.

Contact ViiVConnect at 1-877-844-8872 or ViiVConnect.com for help finding providers, navigating insurance, and financial assistance.

Ask your provider about bridging with oral PrEP while Apretude access is sorted out. Generic Truvada is widely available and costs $30-100/month.

Find a federally qualified health center (FQHC) that offers HIV prevention services at findahealthcenter.hrsa.gov. These centers often have the infrastructure and funding to provide injectable PrEP.

The Bottom Line for Patients in 2026

Apretude is not in a shortage — it's a real medication that's genuinely available and covered for most patients. The challenge is navigating the infrastructure to get it. With persistence, the right resources, and a provider who has invested in offering injectable PrEP, most patients can access Apretude. See our detailed guide on how to find Apretude near you for step-by-step help.